Exp Mol Med.  2010 Mar;42(3):187-194. 10.3858/emm.2010.42.3.019.

TGF-beta-treated antigen presenting cells suppress collagen-induced arthritis through the promotion of Th2 responses

• Jung S
• Park YK
• Lee H
• Shin JH
• Lee GR
• Park SH

• KMID: 946651
• DOI: http://doi.org/10.3858/emm.2010.42.3.019

Abstract

Collagen-induced arthritis (CIA) is mediated by self-reactive CD4+ T cells that produce inflammatory cytokines. TGF-beta2-treated tolerogenic antigen-presenting cells (Tol-APCs) are known to induce tolerance in various autoimmune diseases. In this study, we investigated whether collagen-specific Tol-APCs could induce suppression of CIA. We observed that Tol-APCs could suppress the development and severity of CIA and delay the onset of CIA. Treatment of Tol-APCs reduced the number of IFN-gamma- and IL-17-producing CD4+ T cells and increased IL-4- and IL-5-producing CD4+ T cells upon collagen antigen stimulation in vitro. The suppression of CIA conferred by Tol-APCs correlated with their ability to selectively induce IL-10 production. We also observed that treatment of Tol-APCs inhibited not only cellular immune responses but also humoral immune responses in the process of CIA. Our results suggest that in vitro-generated Tol-APCs have potential therapeutic value for the treatment of rheumatoid arthritis as well as other autoimmune diseases.

Keyword

antigen-presenting cells; arthritis, experimental; autoimmune diseases; immune tolerance; Th1 cells; Th2 cells

MeSH Terms

Animals
Antigen-Presenting Cells/*drug effects/*immunology
Arthritis, Experimental/*immunology
Chickens
Collagen Type II/immunology
Immune Tolerance/drug effects
Mice
Mice, Inbred BALB C
Ovalbumin/immunology
Th1 Cells/drug effects/immunology
Th2 Cells/*drug effects/*immunology
Transforming Growth Factor beta2/*pharmacology